CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mueller, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mueller, N. E.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 237S, March 2003
© 2003 American Association for Cancer Research


Introduction to Session I

Cancers Caused by Infections

Unequal Burdens

Nancy E. Mueller1

Harvard School of Public Health, Department of Epidemiology, Boston, Massachusetts 02115

Introduction

Many people are surprised to learn that cancer can be caused by an infection. There are seven major infectious agents for which there has been sufficient evidence from epidemiological, clinical, and biological studies to be classified as human carcinogens by expert panels of the International Agency for Research on Cancer. These are hepatitis B virus (1) , hepatitis C virus (1) , certain strains of the human papilloma virus (2) , Helicobacter pylori (3) , Epstein-Barr virus (4) , human immunodeficiency virus type 1 (5) , and human T-cell lymphotropic virus type I (5) . In addition, the Kaposi’s sarcoma herpesvirus (or HHV8) is classified as a probable human carcinogen (4) .

In the United States, it is estimated that ~7% of our total cancer incidence is attributable to the effects of one or more of these agents (6) . The incidence of these infection-associated cancers is generally higher among our minority and disadvantaged populations (7) . This excess occurrence likely results from higher infection rates for agents that are transmitted under conditions of crowding or poor hygiene, such as H. pylori. It may be because of increased exposure to blood that is contaminated with agents such as hepatitis C, through reuse of needles for medical procedures or for drug use. It may be because of lack of adequate medical care, such as access to regular cervical screening with prompt follow-up care for abnormalities. Thus, for a variety of reasons, there is an unequal burden of infection-related cancers among our minority and poorer citizens. This is particularly true for cervical cancer caused by certain genital papilloma viruses, liver cancer caused by the hepatitis B and C viruses, and stomach cancer caused by H. pylori.

What are the characteristics of these infectious agents that can cause cancer? The one common feature is that each can become a chronic infection (8) . It is really the persistence, chronic expression, and replication of these agents that can, in some circumstances, lead to malignancy. There are also factors related to the individual carriers of these infections that can influence their probability of developing cancer. The most important factor is age of infection. That is a consistent theme (8) . Usually, very early age of infection is associated with subsequent risk of cancer. In addition, factors such as coinfections or nutritional state that affect the competency of the immune system can modify the risk of malignancy. How common are these infections? Some of these are fairly common; e.g., the majority of women have been or are currently infected with a high-risk strain of human papilloma virus. Does it mean that if I have one of these infections, I am likely to develop cancer from it? The answer is "No"; cancer is really a rare outcome of these infections. Except for the AIDS virus, most carriers of these infections are unaware of their infection and unlikely to experience any serious related illness.

There are also steps along the way where the infection can be prevented or cured. The best prevention is to avoid exposure itself, e.g., by avoiding any contact with blood from another person that might contain viruses with the potential to increase cancer risk. We now have a vaccination against Hepatitis B virus; my grandchildren are all vaccinated. H. pylori infection can be cured in many cases. The most important medical self-care action for prevention of cervical cancer is to have regular cervical screening.

Taken together, there are a variety of strategies that can be used at the individual or community level to reduce the burden from these malignancies. Today, we are going to talk about four of these infections and their impact on the cancer burden on minority and disadvantaged populations.

Footnotes

1 To whom requests for reprints should be addressed, at Harvard School of Public Health, Department of Epidemiology, Kresge Building, Room 802, 677 Huntington Avenue, Boston, MA 02115. E-mail: nmueller{at}hsph.harvard.edu Back

accepted 1/ 6/03.

References

  1. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 59. Hepatitis Viruses. Lyon, France: IARC 1994.
  2. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 64. Human Papillomaviruses. Lyon, France: IARC, 1995.
  3. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61. Schistosomes, Liver Flukes and Helicobacter Pylori. Lyon, France: IARC, 1994.
  4. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 70. Epstein-Barr Virus and Kaposi’s Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon, France: IARC, 1997.
  5. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 67. Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses. Lyon, France: IARC, 1996.
  6. Parkin D. M., Pisani P., Muñoz M., Ferlay J. The global health burden of infection associated cancers. Cancer Surv., 33: 5-33, 1999.
  7. Miller B. A. Kolonel L. N. Bernstein L. Young J. L., Jr. Swanson G. M. West D. Key C. R. Liff J. M. Glover C. S. Alexander G. A.et al eds. . Racial/ethnic patterns of cancer in the United States 1988–1992, National Cancer Institute. NIH Pub. No. 96-4104, NIH Bethesda, MD 1996.
  8. Mueller N., Evans A. S., London T. Viruses Schottenfeld D. Fraumeni J. F., Jr. eds. . Cancer Epidemiology and Prevention, Ed. 2, 502-531, Oxford University Press New York 1996.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mueller, N. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mueller, N. E.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation